Longer trastuzumab duration ( hera : 2 years vs. 1 year ) showed no improvement in dfs or os and a higher rate of cardiac events .
In the neoadjuvant setting ( neoaltto , GeparQuinto , Neosphere ) , trastuzumab alone or in combination with another anti-her2 agent ( lapatinib , pertuzumab ) was compared with either lapatinib or pertuzumab alone and showed superior or equivalent rates of pathologic complete response .
In the adjuvant setting , lapatinib alone or in combination with trastuzumab , compared with trastuzumab alone ( altto ) or with placebo ( teach ) , was not superior in dfs .
BACKGROUND This systematic review addresses the question " What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer ? "
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
BACKGROUND This study aims to describe and compare health-related quality of life ( HRQL ) in patients with node-positive and high-risk node-negative HER2-positive early breast cancer receiving adjuvant docetaxel and trastuzumab-based or docetaxel-based regimens alone . METHODS Eligible patients ( n = 3,222 ) were r and omly assigned to either four cycles of adjuvant doxorubicin and cyclophosphamide followed by four cycles of docetaxel ( AC→T ) or one of two trastuzumab-containing regimens : adjuvant doxorubicin and cyclophosphamide followed by docetaxel plus trastuzumab administered for 1 year ( AC→TH ) or six cycles of docetaxel plus carboplatin combined with trastuzumab administered for 1 year ( TCH ) . The European Organization for Research and Treatment of Cancer ( EORTC ) Quality of Life Question naire C30 and BR-23 were administered at baseline , the start of cycle 4 ( mid ) , and the end of chemotherapy ( EOC ) , as well as at 6 , 12 , and 24 months after chemotherapy . RESULTS Compliance rates for the EORTC question naires were acceptable at 72%-93 % of eligible patients out to the 12-month assessment . Systemic side effect ( SE ) change scores were significantly improved for TCH-treated patients compared with AC→TH and AC→T at EOC , suggesting improved tolerability . Physical functioning ( PF ) was only slightly worse at midpoint for those receiving TCH , compared with patients who were just starting on taxane in an AC→TH regimen , but was otherwise similar between arms . All treatment arms recovered from the deterioration in SE , PF , and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up . CONCLUSION HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option
Longer trastuzumab duration ( hera : 2 years vs. 1 year ) showed no improvement in dfs or os and a higher rate of cardiac events .
In the neoadjuvant setting ( neoaltto , GeparQuinto , Neosphere ) , trastuzumab alone or in combination with another anti-her2 agent ( lapatinib , pertuzumab ) was compared with either lapatinib or pertuzumab alone and showed superior or equivalent rates of pathologic complete response .
In the adjuvant setting , lapatinib alone or in combination with trastuzumab , compared with trastuzumab alone ( altto ) or with placebo ( teach ) , was not superior in dfs .
BACKGROUND This systematic review addresses the question " What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer ? "